Kringle Pharma, Inc. engages in the research and development of treatments for regenerative medicine and cancer therapy. It specializes in the research of hepatocyte growth factor (HGF), an intrinsic factor with an organotrophic role in the regeneration and repair of tissues and organs. It also provides research and development of NK4, a multi-targeted angiogenesis inhibitor and a cancer therapeutic. The company was founded by Kunio Matsumoto and Toshikazu Nakamura on December 21, 2001 and is headquartered in Osaka, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company